Onconetix faces third delisting threat since 2022 IPO
Onconetix's low stock price has triggered yet another warning from the Nasdaq. The company plans to request a hearing with the exchange.
Onconetix's low stock price has triggered yet another warning from the Nasdaq. The company plans to request a hearing with the exchange.